{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:48:46Z","timestamp":1780930126425,"version":"3.54.1"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Tetraphase Pharmaceuticals, Inc."},{"name":"Tetraphase Pharmaceuticals, Inc."}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR\n            <jats:named-content content-type=\"genus-species\">Bacteroides<\/jats:named-content>\n            spp. and\n            <jats:named-content content-type=\"genus-species\">Clostridium difficile<\/jats:named-content>\n            . Eravacycline was potent\n            <jats:italic>in vitro<\/jats:italic>\n            against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and\/or \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations.\n          <\/jats:p>","DOI":"10.1128\/aac.02206-17","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T16:15:22Z","timestamp":1522253722000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Evaluation of the\n            <i>In Vitro<\/i>\n            Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates"],"prefix":"10.1128","volume":"62","author":[{"given":"David R.","family":"Snydman","sequence":"first","affiliation":[{"name":"Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilda V.","family":"Jacobus","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Kerstein","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy H.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/647940"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2016.11.003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00845-15"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_2_10_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Grossman T","year":"2014","unstructured":"Grossman T, O'Brien W, Fyfe C, Sutcliffe J. 2014. Eravacycline is potent against third generation cephalosporin- and carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii and has isolate-specific bactericidal activity, abstr C-1374. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01646-16"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.73"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"e_1_3_2_15_2","volume-title":"Infect Dis Soc Am, ID Week 2016","author":"Bassetti M","year":"2016","unstructured":"Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T, Olesky M, Sutcliffe J. 2016. In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, including multidrug-resistant (MDR) isolates, over a three-year period (2013-15), abstr 1825. Infect Dis Soc Am, ID Week 2016, 26 to 30 October 2016, New Orleans, LA."},{"key":"e_1_3_2_16_2","volume-title":"Infect Dis Soc Am, ID Week 2016","author":"Bassetti M","year":"2016","unstructured":"Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T, Olesky M, Sutcliffe J. 2016. In vitro global surveillance of eravacycline and comparators against Staphylococcus spp. and Enterococcus spp. over a three-year period (2013-15), abstr 1820. Infect Dis Soc Am, ID Week 2016, 26 to 30 October 2016, New Orleans, LA."},{"key":"e_1_3_2_17_2","volume-title":"55th Intersci Conf Antimicrob Agents Chemother\/Int Cong Chemother InfectSan Diego, CA","author":"McDermott L","year":"2015","unstructured":"McDermott L, Jacobus NV, Snydman DR, Kerstein K, Grossman TH, Sutcliffe JA. 2015. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates, abstr C-547. 55th Intersci Conf Antimicrob Agents Chemother\/Int Cong Chemother Infect, 17 to 21 September 2015, San Diego, CA."},{"key":"e_1_3_2_18_2","volume-title":"Activity of eravacycline against anaerobic bacteria from Europe collected in 2013\u201314, abstr 784","author":"Morrissey I","year":"2015","unstructured":"Morrissey I, Sutcliffe J, Hackel M, Hawser S. 2015. Activity of eravacycline against anaerobic bacteria from Europe collected in 2013\u201314, abstr 784. Infect Dis Soc Am, ID Week 2015, 7 to 11 October 2015, San Diego, CA."},{"key":"e_1_3_2_19_2","volume-title":"Star Publishing Co.","author":"Jousimies-Somer HR","year":"2002","unstructured":"Jousimies-Somer HR, Summanem P, Citron DM, Baron EJ, Wexler H, Finegold SM. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Co., Belmont, CA."},{"key":"e_1_3_2_20_2","volume-title":"CLSI document M11-A8","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 8th ed. CLSI document M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"8"},{"key":"e_1_3_2_21_2","volume-title":"CLSI Document M100S","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Performance standards for antimicrobial susceptibility testing, 26th ed. CLSI Document M100S. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"26"},{"key":"e_1_3_2_22_2","volume-title":"Tygacil (tigecycline for injection); sterile, lyophilized powder for intravenous use, 50 mg\/vial)","author":"T. M. Wyeth","year":"2014","unstructured":"T. M. Wyeth. 2014. Product monograph. Tygacil (tigecycline for injection); sterile, lyophilized powder for intravenous use, 50 mg\/vial). T. M. Wyeth, Kirkland, Quebec City, Canada. http:\/\/www.pfizer.ca\/sites\/g\/files\/g10017036\/f\/201410\/TYGACIL_PM_E_168980_17Jan2014.pdf."},{"key":"e_1_3_2_23_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 6.0","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2016","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 6.0. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_6.0_Breakpoint_table.pdf."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3675-3681.2003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409573200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.07.010"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02063.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02206-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02206-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:16:17Z","timestamp":1645478177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02206-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1128\/AAC.02206-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02206-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"2017-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02206-17"}}